Century Therapeutics, Inc. (IPSC)
Nasdaq · Healthcare · Biotechnology
$1.48−3.27%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $268M
- 52-week range
- $0.435 – $3.04
- 52-week change
- +175.68%
- EPS (trailing)
- −$0.93
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $109M (+1556.70%)
- Net income
- −$9.6M
- Operating margin
- −15.8%
- Diluted EPS
- −$0.14
- Free cash flow
- −$105M
From the company’s annual report on SEC EDGAR.
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Headquarters: Philadelphia, United States · 78 employees · centurytx.com